New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
16:25 EDTIMGNInitial findings show new dosing approach for IMGN853 achieves objective
ImmunoGen announced the first findings from company research aimed at optimizing the dosing of its IMGN853 product candidate. Based on findings in the first patients to receive IMGN853, ImmunoGen identified that clinical activity is seen with the compound starting at doses of 3.3 mg/kg and its dose-limiting toxicity is the reversible ocular side effects, blurred vision and keratitis, reported with ADCs in development by several companies. These side effects occurred at IMGN853 doses of 5 mg/kg and above, with dose based on patient total body weight, or TBW. As presented, modeling research conducted by ImmunoGen predicted that dosing IMGN853 using adjusted ideal body weight, or ADJ, rather than TBW should reduce the variability among patients in the concentration of IMGN853 in their blood, as ADJ would better match the dose administered to patient blood volume. Reducing this variability should enable IMGN853 to be well tolerated in more patients at dose levels greater than 3.3 mg/kg. Based on these insights, dosing in the ongoing IMGN853 Phase 1 trial was changed to ADJ several months ago, and the first findings were reported today. The clinical findings to date validate the prediction: none of the patients treated with IMGN853 at 5 mg/kg ADJ have had ocular side effects of any grade. This compares with 4 of 10 patients treated at 5 mg/kg TBW. IMGN853 dose escalation above 5 mg/kg ADJ is ongoing.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
10:00 EDTIMGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:44 EDTIMGNImmunoGen downgraded to Hold from Buy at Cantor
Cantor Fitzgerald analyst Mara Goldstein downgraded ImmunoGen to Hold citing the recent really in shares. The analyst raised her price target for the stock to $21 from $12.
July 31, 2015
06:36 EDTIMGNImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
06:34 EDTIMGNImmunoGen sees FY16 revenue $70M-$80M, consensus $87.4M
Sees FY16 operating expenses $175M-$180. Sees FY16 net loss to be 120M-$125M. Sees FY16 cash used in operations $100M-$105M. Sees FY16 CapEx $13M-$15M. Sees FY16 cash and marketable securities anticipated to be $165M-$170M.
06:32 EDTIMGNImmunoGen reports Q4 EPS (35c), consensus (35c)
Reports Q4 revenue $12.61M, consensus $15.42.
July 29, 2015
08:29 EDTIMGNImmunoGen price target raised to $24 from $13 at Oppenheimer
Oppenheimer hiked its price target on ImmunoGen as the firm thinks that updates on its '853 drug will better frame the drug's value. The firm believes that several other positive catalysts will propel the stock higher in 2016. It keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use